专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08828442B2 Pharmaceutical solid dispersions 有权
标题翻译：药物固体分散体
公开(公告)号：US08828442B2
公开(公告)日：2014-09-09
申请号：US13610350
申请日：2012-09-11
申请人： Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Ravi M. Shanker
发明人： Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Ravi M. Shanker
IPC分类号： A61K31/44 , A61K9/16 , A61K9/14
CPC分类号： A61K9/1635 , A61K9/146 , A61K9/1652
摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.
摘要翻译：组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。分散体中药物的至少大部分是无定形的。组合物还包括增加使用环境中药物浓度的浓度增强聚合物。稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

2. 发明授权

US08389006B2 Pharmaceutical compositions of adsorbates of amorphous drug 有权
公开(公告)号：US08389006B2
公开(公告)日：2013-03-05
申请号：US12180769
申请日：2008-07-28
申请人： Walter C. Babcock , Dwayne T. Friesen , Ravi M. Shanker , Daniel T. Smithey , Ralph Tadday
发明人： Walter C. Babcock , Dwayne T. Friesen , Ravi M. Shanker , Daniel T. Smithey , Ralph Tadday
IPC分类号： A61K9/28 , A61K9/14 , A61K9/00
CPC分类号： A61K31/519 , A61K9/143 , A61K9/146 , A61K9/1611 , A61K9/1652 , A61K31/405 , A61K31/47 , A61K31/496 , A61K31/498
摘要： Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer.

3. 发明授权

US08883209B2 Pharmaceutical solid dispersions 有权
标题翻译：药物固体分散体
公开(公告)号：US08883209B2
公开(公告)日：2014-11-11
申请号：US12760393
申请日：2010-05-25
申请人： Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Ravi M. Shanker
发明人： Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Ravi M. Shanker
IPC分类号： A61K31/404 , A61K9/16 , A61K9/14
CPC分类号： A61K9/1635 , A61K9/146 , A61K9/1652
摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.
摘要翻译：组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。分散体中药物的至少大部分是无定形的。聚合物的玻璃化转变温度至少为100℃，相对湿度为百分之五十。本发明的另一方面包括相同的组成，不同之处在于分散体在50％的相对湿度下具有至少50℃的玻璃化转变温度。在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。分散体中药物的至少大部分是无定形的。组合物还包括增加使用环境中药物浓度的浓度增强聚合物。稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

4. 发明授权

US08481081B2 Pharmaceutical solid dispersions 有权
标题翻译：药物固体分散体
公开(公告)号：US08481081B2
公开(公告)日：2013-07-09
申请号：US10459808
申请日：2003-06-10
申请人： Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Ravi M. Shanker
发明人： Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Ravi M. Shanker
IPC分类号： A61K9/14
CPC分类号： A61K9/1635 , A61K9/146 , A61K9/1652
摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.
摘要翻译：组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。分散体中药物的至少大部分是无定形的。聚合物的玻璃化转变温度至少为100℃，相对湿度为百分之五十。本发明的另一方面包括相同的组成，不同之处在于分散体在50％的相对湿度下具有至少50℃的玻璃化转变温度。在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。分散体中药物的至少大部分是无定形的。组合物还包括增加使用环境中药物浓度的浓度增强聚合物。稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

5. 发明授权

US08236328B2 Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers 有权
标题翻译：与聚合物混合的无定形药物的分散体的药物组合物
公开(公告)号：US08236328B2
公开(公告)日：2012-08-07
申请号：US12217700
申请日：2008-07-08
申请人： Walter C. Babcock , William J. Curatolo , Dwayne T. Friesen , Rodney J. Ketner , Julian B. Lo , James A. S. Nightingale , Ravi M. Shanker , James B. West
发明人： Walter C. Babcock , William J. Curatolo , Dwayne T. Friesen , Rodney J. Ketner , Julian B. Lo , James A. S. Nightingale , Ravi M. Shanker , James B. West
IPC分类号： A61K9/00 , A61K9/14
CPC分类号： A61K9/146
摘要： A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.
摘要翻译：药物组合物包含包含低溶解度药物和与浓度增强聚合物组合的基质的分散体。至少大部分药物在分散体中是无定形的。组合物改善药物在分散体中的稳定性和/或药物在使用环境中的浓度。

6. 发明授权

US08202912B2 Pharmaceutical compositions providing enhanced drug concentrations 有权
标题翻译：提供增强药物浓度的药物组合物
公开(公告)号：US08202912B2
公开(公告)日：2012-06-19
申请号：US13208305
申请日：2011-08-11
申请人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
发明人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
IPC分类号： A61K47/32 , A61K9/14 , A61K9/16 , A61K9/22
CPC分类号： A61K47/38 , A61K9/146 , A61K9/1629 , A61K9/1652 , A61K31/135 , A61K31/404 , A61K31/4178 , A61K31/4375 , A61K31/496 , A61K31/517
摘要： A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
摘要翻译：将溶解度改善形式的药物与足够量的浓度增强聚合物组合，使得组合在使用环境中相对于包含相同量的相同溶解度改善形式的药物的对照提供了显着增强的药物浓度没有浓度增强聚合物。

7. 发明授权

US08147872B2 Pharmaceutical compositions of drugs and neutralized acidic polymers 有权
标题翻译：药物的药物组合物和中和的酸性聚合物
公开(公告)号：US08147872B2
公开(公告)日：2012-04-03
申请号：US11213118
申请日：2005-08-26
申请人： Marshall Crew , Dwayne T. Friesen , Rodney J. Ketner , Ravi M. Shanker , James B. West
发明人： Marshall Crew , Dwayne T. Friesen , Rodney J. Ketner , Ravi M. Shanker , James B. West
IPC分类号： A61K9/14 , A61K9/00 , A61K31/716
CPC分类号： A61K9/1611 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1652 , A61K31/00 , A61K31/404 , A61K31/405 , A61K31/4439 , A61K31/4706 , A61K31/4745 , A61K31/496 , A61K31/498 , A61K31/7024 , A61K31/717 , A61K2300/00
摘要： Pharmaceutical compositions comprised of low-solubility and/or acid-sensitive drugs and neutralized acidic polymers are disclosed.
摘要翻译：公开了由低溶解度和/或酸敏感性药物和中和的酸性聚合物组成的药物组合物。

8. 发明授权

US08026286B2 Pharmaceutical compositions providing enhanced drug concentrations 有权
标题翻译：提供增强药物浓度的药物组合物
公开(公告)号：US08026286B2
公开(公告)日：2011-09-27
申请号：US09742785
申请日：2000-12-20
申请人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
发明人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
IPC分类号： A61K47/32 , A61K9/14 , A61K9/16 , A61K9/22
CPC分类号： A61K47/38 , A61K9/146 , A61K9/1629 , A61K9/1652 , A61K31/135 , A61K31/404 , A61K31/4178 , A61K31/4375 , A61K31/496 , A61K31/517
摘要： A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
摘要翻译：将溶解度改善形式的药物与足够量的浓度增强聚合物组合，使得组合在使用环境中相对于包含相同量的相同溶解度改善形式的药物的对照提供了显着增强的药物浓度没有浓度增强聚合物。

9. 发明申请

US20100256110A1 PHARMACEUTICAL SOLID DISPERSIONS 有权
标题翻译：药物固体分散体
公开(公告)号：US20100256110A1
公开(公告)日：2010-10-07
申请号：US12760393
申请日：2010-05-25
申请人： Walter C. Babcock , Dwayne T. Friesen , James A.S. Nightingale , Ravi M. Shanker
发明人： Walter C. Babcock , Dwayne T. Friesen , James A.S. Nightingale , Ravi M. Shanker
IPC分类号： A61K31/404 , A61K31/44 , A61P9/12 , A61P7/02 , A61P3/10 , A61P35/00 , A61P15/10 , A61P29/00 , A61P25/18 , A61P31/04 , A61P31/10 , A61P25/16 , A61P25/28 , A61P31/12
CPC分类号： A61K9/1635 , A61K9/146 , A61K9/1652
摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.
摘要翻译：组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。分散体中药物的至少大部分是无定形的。聚合物的玻璃化转变温度至少为100℃，相对湿度为百分之五十。本发明的另一方面包括相同的组成，不同之处在于分散体在50％的相对湿度下具有至少50℃的玻璃化转变温度。在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。分散体中药物的至少大部分是无定形的。组合物还包括增加使用环境中药物浓度的浓度增强聚合物。稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

10. 发明授权

US09023393B2 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials 有权
标题翻译：无定形药物和亲脂性微相形成材料的吸附物的药物组合物
公开(公告)号：US09023393B2
公开(公告)日：2015-05-05
申请号：US10910448
申请日：2004-08-03
申请人： Walter C. Babcock , Dwayne T. Friesen , Ravi M. Shanker , Daniel T. Smithey
发明人： Walter C. Babcock , Dwayne T. Friesen , Ravi M. Shanker , Daniel T. Smithey
IPC分类号： A61K9/14 , A61K9/16 , A61K47/44 , A61K47/12 , A61K47/26
CPC分类号： A61K9/143 , A61K9/1611 , A61K47/12 , A61K47/26 , A61K47/44
摘要： A pharmaceutical composition comprises a solid adsorbate comprising a drug adsorbed onto a substrate and a lipophilic microphase-forming material. The solid adsorbate may also be co-administered with a lipophilic microphase-forming material to an in vivo use environment. The compositions of the present invention enhance the concentration of drug in a use environment.
摘要翻译：药物组合物包含固体吸附物，其包含吸附在基底上的药物和形成亲脂性的微相形成材料。固体吸附物质也可以与亲脂性微相形成材料共同施用于体内使用环境。本发明的组合物在使用环境中增强药物的浓度。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式